Evidence map›Paper›PMID 27565381›Full record

ReviewPharmacological research2016

Esophageal cancer: The latest on chemoprevention and state of the art therapies.

Gregoire F Le Bras, Muhammad H Farooq, Gary W Falk, Claudia D Andl

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmacological research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Long Non-coding RNA DANCR in Cancer: Roles, Mechanisms, and Implications.Frontiers in cell and developmental biology · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Gregoire F Le BrasBurnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, United States.
Muhammad H FarooqBurnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, United States.
Gary W FalkDivision of Gastroenterology, Department of Internal Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Claudia D AndlBurnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, United States. Electronic address: Claudia.andl@ucf.edu.

Funding

The role of Activin A signaling in esophageal cell invasionR01DK094900 · NIDDK · VANDERBILT UNIVERSITY · PI ANDL, CLAUDIA D · 2012 to 2016
$1.6M
NIDDK NIH HHS R01 DK094900
6 · The paper itself

Abstract

Esophageal cancer is currently the 8th most common cancer worldwide and the 6th leading cause of cancer-related mortality. Despite remarkable advances, the mortality for those suffering from esophageal cancer remains high, with 5-year survival rates of less than 20%. In part, because most patients present with late-stage disease, long-term survival even after resection and therapy is disappointingly low. As we will discuss in this review, multiple characteristics specific to the disease stage and patient must be considered when choosing a treatment plan. This article will summarize current standard therapies, potential application of chemoprevention drugs and the promise and partial failure of personalized medicine, as well as novel treatments addressing this disease.

Indexed as

AnimalsAntineoplastic AgentsChemopreventionEsophageal NeoplasmsHumansSurvival RateAntineoplastic AgentsCancer preventionChemotherapyEsophageal cancerImmunotherapyTreatment

Identifiers

PMID27565381
PMCPMC5107116

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.